-+ 0.00%
-+ 0.00%
-+ 0.00%

enVVeno Medical To Present 3-Yr Data From SAVVE, US Pivotal Study Of VenoValve, At 53rd Annual VEITH Symposium

Benzinga·11/20/2026 13:47:04
Diffusion vocale

Three-year follow-up data from the VenoValve pivotal trial shows sustained clinical improvement and continued patient benefit at 36 months compared to baseline, with statistically significant improvements in disease severity, leg pain, symptoms and quality of life

Company also highlights its next-generation, non-surgical enVVe system and remains on track to enroll the first subject in the TAVVE pivotal study by year-end 2026

IRVINE, CA / ACCESS Newswire / November 20, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, will present three-year data from SAVVE, the U.S. pivotal study of the VenoValve® today at the 53rd Annual Vascular and Endovascular Issues, Techniques and Horizons (VEITH) Symposium in New York City. The data, which will be presented by Dr. David Dexter of Sentara Vascular Specialists, shows sustained, statistically significant improvements in the revised Venous Clinical Severity Score (rVCSS), leg pain and quality-of-life measures in patients with severe chronic venous insufficiency (CVI). The presentation will also highlight enVVe®, the Company's next-generation, non-surgical transcatheter replacement venous valve.